uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
uniQure N.V.’s Chief Medical Officer Walid Abi-Saab reported new equity awards and a small automatic share sale. He was granted stock options for 67,200 shares at an exercise price of $0.00 and 41,700 restricted share units, each representing the right to receive one ordinary share.
The restricted share units vest in three equal annual installments starting one year after the grant date, subject to continued service. The stock options vest 25% on the first anniversary and 6.25% quarterly thereafter until fully vested, also contingent on continued service.
Upon vesting of restricted share units, 808 ordinary shares were sold at a weighted average price of $9.06, within a $9.00–$9.22 range, solely to cover estimated withholding taxes under automatic sale instructions, not as a discretionary trade. After these transactions, he directly owned 189,669 ordinary shares.
uniQure N.V.’s Chief Legal Officer, Jeannette Potts, reported a mix of equity awards and an automatic share sale. She received a grant of 57,200 stock options with an exercise price of $0.00 per share and 35,400 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments starting one year after the grant date, contingent on her continued service. The stock options vest 25% after one year and 6.25% quarterly thereafter. In connection with vesting, 3,412 ordinary shares were sold at a weighted average price of $9.06, within a $9.00–$9.22 range, solely to cover estimated withholding taxes under automatic sale instructions, and were not a discretionary trade.
uniQure N.V.’s Chief Financial Officer, Christian Klemt, reported a mix of equity awards and an automatic tax-related sale. On March 4, 2026, he received a stock option for 63,900 shares at an exercise price of $0.00 and a grant of 39,600 restricted share units, each representing one ordinary share.
The restricted share units vest in three equal annual installments beginning on the first anniversary of grant, subject to his continued relationship with the company. On the same date, 12,000 ordinary shares were sold at a weighted average price of $9.06 per share, within a price range of $9.00 to $9.22, solely to cover estimated withholding taxes under automatic sale instructions, not as a discretionary trade.
uniQure NV reports a proposed sale of ordinary shares and recent insider dispositions. The filing notifies a proposed sale of 12,000 ordinary shares through Citigroup Global Markets on 03/04/2026. The notice also lists 24,333 restricted stock units vesting on 03/04/2026 as compensation. Recent reported dispositions by Christian Klemt total 18, + (6,217 and 12,832) ordinary shares sold in February–March 2026 with reported proceeds shown in the excerpt.
uniQure NV submitted a Form 144 disclosing the proposed sale of 33,000 ordinary shares underlying restricted stock units that vest on 03/04/2026. The filing also reports prior open-market sales by Matthew Kapusta of 12,378 shares on 02/25/2026 ($295,306.90) and 34,437 shares on 03/02/2026 ($342,586.16).
uniQure N.V. CEO and Managing Director Matthew C. Kapusta reported an automatic open-market sale of 34,437 ordinary shares on March 2, 2026 at an average price of $9.95 per share. The filing explains the shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under automatic instructions, so the sale was not a discretionary trade. After this transaction, Kapusta held 604,639 ordinary shares. The reported price reflects a weighted average from multiple trades between $9.67 and $10.25 per share.
uniQure N.V.’s Chief Financial Officer, Christian Klemt, reported an automatic tax-related share sale. On March 2, 2026, he sold 12,532 ordinary shares in an open-market transaction at a weighted average price of $9.95 per share. The shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under automatic sale instructions in the RSU agreement, meaning the sale was not a discretionary trade. Following the transaction, he directly owned 198,981 ordinary shares.
uniQure N.V.’s Chief Legal Officer, Jeannette Potts, reported an automatic sale of 8,578 ordinary shares. The shares were sold on March 2, 2026 in open-market transactions at a weighted average price of $9.95 per share.
According to the disclosure, the sale occurred upon the vesting of restricted share units and was made solely to cover estimated withholding taxes under automatic sale instructions, meaning it was not a discretionary trade by Potts. Following these transactions, she directly owned 106,495 ordinary shares of uniQure N.V.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an automatic sale of 1,660 ordinary shares in an open-market transaction at a weighted average price of $9.95 per share. The shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under pre-set instructions, and were not a discretionary trade. After this transaction, Abi-Saab直接 owns 148,777 ordinary shares. The sale price reflected multiple trades between $9.67 and $10.25.